The document discusses the disparity between the growth rate of clinical trial compounds and population recruitment, highlighting that patient recruitment bottlenecks slow down drug accessibility. It argues the need for a stronger focus on recruitment strategies, despite only 2% of sponsors prioritizing it. The text also reveals various challenges faced in recruitment and the effectiveness of traditional recruitment methods.

1. The growth rate of compounds in
development far exceeds population
growth and the number of investigators
remains mostly flat. Because of this, patient
recruitment for clinical trials functions as a
in Patient Recruitment bottleneck in the process. The industry has
to increase its focus on Patient Recruitment.
Priorities
Faster patient recruitment leads to fewer delays in clinical trials, which means getting drugs on the shelf quicker. So
why do only 2% of sponsors rank patient recruitment strategy as the most important when selecting a service provider?
What would 30% lower costs mean?
47% $1.5-$2M 18-24 months $1,111/day
Cost of an average Length of an average 30% savings of an average Phase II Study.
Phase II Study. Phase II Study.
of clinical development
decision-makers would vs.
prefer a 30% lower
clinical trial cost than
10% faster patient
recruitment What would 10% faster patient $1,885,000/day
recruitment mean? Revenue generated per day by The 100th
best selling drug in 3Q2012 (Stelara)
Viewpoints
Clinical trials involve five main groups, each with different views and motivations. Here’s what they’re saying
about clinical trials:
69% 28% 76% 70% 233%
said they have not said that inclusion/exclusion said they are involved in said the hardest part of increase in patients
participated in clinical criteria have the single the right amount, or too patient recruitment is required per NDA from
trials because they biggest impact on patient many clinical trials. finding the 1500 in the 1970s to
were not made aware recruitment success. right investigators. more than 5000 today.
of any trials.
Patients Site Coordinators Investigators Sponsors FDA
Implications
11% 37% 39% 13%
of sites in a given trial fail of sites in a given trial of sites in a given trial meet of sites in a given trial
to enroll a single patient under-enroll their enrollment targets exceed their targets
The patient recruitment methods with the highest value, tend to be the more traditional methods:
Dr. Referral Mail from Doctor Custom Website
Local Newspaper
Radio
Poster in Doctor’s Office
Affinity Groups
sources: clinicaltrials.gov, Tufts, ISR Reports Data Copyright 2013 Industry Standard Research | ISRreports.com | info@ISRreports.com